GSK plc (GSK)
GSK trades on NYSE in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 20-F (ifrs-full:Revenue), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1131399/000113139926000004/0001131399-26-000004-index.htm. Net income: SEC 20-F (ifrs-full:ProfitLossAttributableToOwnersOfParent), fiscal year ended 2025-12-31. Converted from GBP at 0.7561 per USD (today's ECB or Federal Reserve reference rate).
Profile
| Field | Value |
|---|---|
| Ticker | GSK on NYSE |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United Kingdom |
| IPO year | 2022 |
| SEC CIK | 0001131399 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | United Kingdom |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $43.2B |
| Net income | $7.6B |
| Operating income | $10.5B |
| Net margin | 17.5% |
| Operating margin | 24.3% |
| Revenue growth | +4.1% |
| Cash | $4.5B |
| Total assets | $80.8B |
| P/E (computed) | 13.5× |
| P/S (computed) | 2.4× |
Reported in GBP; shown in US dollars.
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 20-F 2026-03-06 |
| Cash and burn | 3.4B GBP cash; operating cash flow 1.9B GBP a quarter. | Report 2025-12-31 |
| Shares outstanding | 2,157,722,513 (2025-12-31); 2,157,151,867 a year earlier; 2,155,671,671 three years earlier. the newest SEC cover-page count is from 2025-12-31; shares issued since then are not in these figures. | Cover page 2025-12-31 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Delisting | 25-NSE filed | 25-NSE 2025-05-15 |
| Auditor | Deloitte LLP, London, United Kingdom | PCAOB Form AP 2026-03-30 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Annual results
| Fiscal year | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| FY 2025 2025-12-31 | 32.7B GBP | 5.7B GBP | 7.7B GBP | 3.4B GBP | 14.5B GBP | 32.7B GBP | 20-F 2026-03-06 |
| FY 2024 2024-12-31 | 31.4B GBP | 2.6B GBP | 6.6B GBP | 3.9B GBP | 13.1B GBP | 31.4B GBP | 20-F 2026-03-06 |
| FY 2023 2023-12-31 | 30.3B GBP | 4.9B GBP | 6.8B GBP | 2.9B GBP | 15.0B GBP | 30.3B GBP | 20-F 2025-03-03 |
| FY 2022 2022-12-31 | 29.3B GBP | 15.0B GBP | 7.4B GBP | 3.7B GBP | 17.2B GBP | 29.3B GBP | 20-F 2024-03-05 |
| FY 2021 2021-12-31 | 24.7B GBP | 4.4B GBP | 8.0B GBP | 4.3B GBP | 19.8B GBP | 24.7B GBP | 20-F 2024-03-05 |
| FY 2020 2020-12-31 | 24.4B GBP | 5.7B GBP | 8.4B GBP | 6.3B GBP | 20.8B GBP | 24.4B GBP | 20-F 2023-03-10 |
| FY 2019 2019-12-31 | 33.8B GBP | 4.6B GBP | 8.0B GBP | 4.7B GBP | 25.2B GBP | 33.8B GBP | 20-F 2022-03-08 |
| FY 2018 2018-12-31 | 30.8B GBP | 3.6B GBP | 8.4B GBP | 3.9B GBP | 21.6B GBP | 30.8B GBP | 20-F 2021-03-12 |
From SEC XBRL company facts (annual reports only: 20-F or 40-F). Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months). Amounts in GBP.
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B2 | 2026-09-10 |
| Latest annual report | 20-F | 2026-03-06 |
| Latest quarterly / interim BEXSERO BOOSTER RECEIVES POSITIVE CHMP OPINION | 6-K | 2026-11-13 |
Source: SEC EDGAR submissions feed, 1,000 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +0.2% |
| 1 month | +9.0% |
| 3 months | 0.0% |
| Year to date | +2.9% |
| 1 year | +4.8% |
| From 52-week high | -17.5% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| REGN | Regeneron Pharmaceuticals Inc. | $952.40 | -0.32% | $98.5B |
| SNY | Sanofi ADS | $48.39 | +0.04% | $118.0B |
| BMY | Bristol-Myers Squibb Company | $62.93 | -0.79% | $128.6B |
| VRTX | Vertex Pharmaceuticals Incorporated | $537.79 | -0.15% | $136.4B |
| TAK | Takeda Pharmaceutical Company Limited | $21.59 | +0.75% | $68.2B |
| PFE | Pfizer Inc. | $28.86 | -0.10% | $164.5B |
| NVO | Novo Nordisk A/S | $41.60 | -0.07% | $184.2B |
| ABT | Abbott Laboratories | $107.45 | -0.99% | $186.1B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier